

PATIENT FOCUSED, EVIDENCE-BASED APPROACH

NYTV VIRTUAL 2020

**THURSDAY, DECEMBER 10th, 2020** 

# **COURSE DIRECTORS**

Samin K. Sharma, MD, FACC, MSCAI Annapoorna S. Kini, MD, MRCP, FACC Gilbert H. Tang, MD, MSc, MBA, FRCSC, FACC Stamatios Lerakis, MD, PhD, FACC, FASE, FSCCT Roxana Mehran, MD, FACC, FACP, FESC, MSCAI



Follow Us @NYTV\_Live #nytvvirtual #nytv2020

**Register Online** 

www.nytranscathetervalves.org



#### PROGRAM OVERVIEW

Structural heart disease refers to a defect in the heart's valves, walls, or chambers. The most common types of structural heart disease are aortic valve disease, mitral valve disease, tricuspid and pulmonic valve disease, hypertrophic cardiomyopathy and congenital heart disease, such as atrial septal defect and ventricular septal defect.

This **New York Transcatheter Valves** course is poised to help healthcare professionals stay current on new and emerging approaches in the diagnosis, management and treatment of valvular and structural heart disease. A robust agenda combines individual and collective opinions from field expert clinicians and scholars. The educational format will consist of recorded lectures, live transcatheter procedures with moderated discussions and live interactive Q&A's with our expert faculty.

## TARGET AUDIENCE

# This course is specifically designed for:

Interventional Cardiologists, Invasive Cardiologists, Cardiothoracic Surgeons, Interventional Radiologists, Interventional Fellows in Training, Nurses, Technicians and other Allied Health Care Professionals who work in Structural Heart Disease.

## **LEARNING OBJECTIVES**

- Appraise new and upcoming technologies in the management of structural heart disease to determine their benefit for patients.
- Present indications, techniques, outcomes, and complications for transcatheter valve intervention in patients with native valve disease and bioprostectic valve dysfunction.
- Evaluate the rationale, challenges, and necessity of the heart team approach to valvular heart disease, and the functionality of the team within a center of excellence.
- Assess the barriers to care in patients with valvular heart disease with specific attention to current gaps in the timely delivery of percutaneous and surgical interventions.

## **ACCREDITATION**

The Icahn School of Medicine at Mount Sinai is accredited by the Accreditation Council for Continuing Medical Education to provide Continuing Medical Education for physicians.

#### CREDIT DESIGNATION.

The Icahn School of Medicine at Mount Sinai designates this live activity for a maximum of 5.25 AMA PRA Category 1 Credit(s)<sup>TM</sup>. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

## **VERIFICATION OF ATTENDANCE**

Verification of attendance will be provided to all professionals.

## CONFERENCE INFORMATION.

For additional information, please email cme@mssm.edu.

# **REGISTRATION FEES**

This course will be complimentary but, if you would like to claim CME credit, there is a \$25 fee.



AGENDA	
8:00 – 8:05am	WELCOME & INTRODUCTION Annapoorna S. Kini, MD; Stamatios Lerakis, MD; Roxana Mehran, MD; Samin K. Sharma, MD; Gilbert Tang, MD
8:05 – 8:30am	<b>Top Ten Advances in Transcatheter Valve Therapy 2020</b> <i>Samin K. Sharma, MD</i>
8:30 – 8:55am	KEYNOTE LECTURE Valvular Heart Disease in the COVID Era: The Path Forward Patrick T. O'Gara, MD
SESSION 1:	TAVR HOT TOPICS IN 2020 AND FUTURE DIRECTIONS Moderator: Roxana Mehran, MD
8:55 – 9:20am	LIVE CASE #1  Operators: Samin K. Sharma, MD; Annapoorna S. Kini, MD; Gilbert Tang, MD; Stamatios Lerakis, MD  Panelists: Alexandre Abizaid, MD; Samir Kapadia, MD; Michael Mack, MD; Didier Tchètchè, MD
9:20 – 9:30am	Adapting to Change in Structural Heart Disease Training Michael Mack, MD
9:30 – 9:40am	Current Update on Next Generation TAVR Valves Alexandre Abizaid, MD
9:40 – 9:50am	TAVR in Bicuspid Valve Raj Makkar, MD
9:50 – 10:00am	TAVR in Small Annulus: The SMART Trial Howard C. Herrmann, MD
10:00 – 10:10am	Neuro-Protection in TAVR: Is it Effective? Samir Kapadia, MD
10:10 – 10:20am	<b>Update on Pharmacology Post TAVR: Future Directions</b> <i>George Dangas, MD</i>
10:20 – 10:30am	TAVR and CAD: Rationale and Design of the COMPLETE TAVR Trial David E. Wood, MD
10:30 – 10:40am	Failed TAVR: Results from Surgical Explants Vinod Thourani, MD
10:40 – 10:50am	Coronary Access Post TAVR: TAVRCathAID Annapoorna S. Kini, MD

## 11:05 - 11:35am LIVE CASE #2

10:50 - 11:05am

Moderator: George Dangas, MD

LIVE ROUND TABLE Q&A

Operators: Samin K. Sharma, MD; Annapoorna S. Kini, MD; Gilbert Tang, MD;

Stamatios Lerakis, MD

Panelists: Howard C. Herrmann, MD; Saibal Kar, MD; Raj Makkar, MD;

Alexandre Abizaid, MD; George Dangas, MD; Howard C. Herrmann, MD;

Samir Kapadia, MD; Raj Makkar, MD; Patrick T. O'Gara, MD;

Vinod Thourani, MD; David E. Wood, MD

Vinod Thourani, MD; David E. Wood, MD

REGISTER ONLINE www.nytranscathetervalves.org

11:35 – 11:45am BREAK/VISIT VIRTUAL EXHIBIT HALL

SESSION 2: TMVR: HOT TOPICS IN 2020 AND FUTURE DIRECTIONS

Moderator: Eberhard Grube, MD

11:45 – 12:00pm Next Generation Mitral Devices for Repair/Replacement

Eberhard Grube, MD

12:00 – 12:15pm Update on Mitral Clip: COAPT and More

Gregg Stone, MD

12:15 – 12:35pm **LIVE ROUND TABLE Q&A** 

Saibal Kar, MD and Gregg Stone, MD

SESSION 3: TRICUSPID VALVE: NOT FORGOTTEN, FRONT AND CENTER

12:35 – 12:50pm Tricuspid Valve Disease: Pathophysiology and Evolving Therapies

Saibal Kar, MD

12:50 – 1:05pm Planning and Results of Transcatheter Tricuspid Valve Therapy

Didier Tchètchè, MD



1:05 – 1:25pm LIVE Q&A

Alexandre Abizaid, MD; Howard C. Herrmann, MD; Eberhard Grube, MD; Samir Kapadia, MD; Saibal Kar, MD; Annapoorna S. Kini, MD;

Stamatios Lerakis, MD; Raj Makkar, MD; Roxana Mehran, MD; Samin K. Sharma, MD; Gregg Stone, MD; Gilbert Tang, MD; Didier Tchètchè, MD; Vinod Thourani, MD; David E. Wood, MD

1:25 – 1:30pm **CONCLUSION** 

Annapoorna S. Kini, MD; Stamatios Lerakis, MD; Roxana Mehran, MD;

Samin K. Sharma, MD; Gilbert Tang, MD

## FACULTY DISCLOSURE

It is the policy of ISMMS to ensure objectivity, balance, independence, transparency, and scientific rigor in all CME sponsored educational activities. All faculty participating in the planning or implementation of a sponsored activity are expected to disclose to the audience any relevant financial relationships and to assist in resolving any conflict of interest that may arise from the relationship. Presenters must also make a meaningful disclosure to the audience of their discussions of unlabeled or unapproved drugs or devices. This information will be available as part of the course material.

REGISTER ONLINE www.nytranscathetervalves.org

# **FACULTY**





## **COURSE DIRECTORS**

## Samin K. Sharma, MD, FACC, MSCAI

Senior Vice President, Operations & Quality, Mount Sinai Heart Director, Interventional Cardiology, Mount Sinai Health System Anandi Lal Sharma Professor of Medicine (Cardiology)

# Annapoorna S. Kini, MD, MRCP, FACC

Director, Cardiac Catheterization Laboratory Director, Structural Heart Disease Program Zena and Michael A. Weiner Professor of Medicine

## Gilbert H. Tang, MD, MSc, MBA, FRCSC, FACC

Surgical Director, Structural Heart Program Associate Professor Cardiovascular Surgery

# Stamatios A. Lerakis, MD, PhD, FACC, FASE, FSCCT

Director of Nonivasive Cardiology Director of Imaging for Structural and Valve Interventions Professor of Medicine

## Roxana Mehran, MD, FACC, FACP, FESC, MSCAI

Director, Interventional Cardiovascular Research and Clinical Trials Professor of Medicine (Cardiology) Professor of Population Health Science and Policy

# MOUNT SINAI FACULTY\_

# George D. Dangas, MD, PhD, FACC, MSCAI

Director, Cardiovascular Innovation Professor of Medicine (Cardiology) Professor of Surgery (Vascular)

## Gregg W. Stone, MD

Director of Academic Affairs for the Mount Sinai Heart Health System Professor of Medicine (Cardiology)

## **GUEST FACULTY**

## Alexandre Abizaid, MD, PhD, FACC

Director of Interventional Cardiology Dante Pazzanese Institute of Cardiology São Paulo, Brazil

#### Eberhard Grube, MD, FSCAI

Head CIIC University Hospital Bonn Bonn, Germany

#### Howard C. Herrmann, MD

Health System Director for Interventional Cardiology Director, Cardiac Catheterization Lab Hospital of the University of Pennsylvania Philadelphia, PA

## Samir Kapadia, MD

Chairman of the Department of CV Medicine Professor of Medicine Cleveland Clinic Cleveland, Ohio

#### Saibal Kar, MD, FACC, FSCAI

Director of Structural Heart Disease and Research HCA Healthcare Los Angeles, CA

# Michael J. Mack, MD

Medical Director of Cardiovascular Services Chairman of the BSW The Heart Hospital Baylor Scott & White Health System Dallas, TX

# Raj Makkar, FACC, FSCAI

Vice President of Cardiovascular Innovation Executive Director, Cardiac Interventional Services Director, Interventional Cardiology Research Program Cedars-Sinai Hospital Los Angeles, CA

# Patrick T. O'Gara, MD

Director of Strategic Planning, Division of CV Medicine Watkins Family Distinguished Chair in Cardiology Brigham and Women's Hospital Boston, MA

## Didier Tchétché, MD, PhD

Director of the Structural Heart Disease Department Clinique Pasteur Toulouse, France

## Vinod Thourani, MD

Department of Cardiovascular Surgery Marcus Heart and Vascular Center Piedmont Heart Institute Atlanta, GA

## David Wood, MD, FRCPC, FACC, FESC

Director, Centre for Cardiovascular Innovation Head, Division of Cardiology and Medical Director, Professor, University of British Columbia Vancouver, Canada



# Icahn School of Medicine at Mount Sinai

The Page and William Black Post-Graduate School One Gustave L. Levy Place, Box 1193 New York, NY 10029-6574

